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Introduction
Hyperlipidaemia is an established reversible risk fac-
tor for coronary heart disease.1,2 However, there is
little positive or negative evidence for benefits of
lipid lowering therapy in peripheral vascular disease,3
and no specific trials looking at HMG-CoA reductase
inhibitors (statins), in these people. Peripheral vascu-
lar disease and coronary heart disease have a clear
association,4 and current recommendations5±7 for
lipid lowering in coronary artery disease suggest
treating all people with demonstrable vascular disease
and a total cholesterol  5 mmol/l. Therefore, at pre-
sent the best we can infer for the management of
arterial disease is based on information for cardiac
disease. We have examined a population of patients
presenting with suspected lower limb arterial disease
and assessed their need for statin therapy by assessing
their cardiac risk factors.
Methods
A lipid profile and cardiovascular history were
recorded on all new referrals to a vascular clinic with
symptoms suggestive of intermittent claudication
during the period February 1999±June 2002. The
presence of lower limb arterial disease was assessed
by ankle-brachial pressure index, exercise testing,
duplex ultrasound and, if appropriate, arteriography.
A total cholesterol 5 mmol/l was used as the thresh-
old for treatment.
Results
Of the 697 new referrals, 485 (70%) patients had lower
limb arterial disease ± of whom 297 had lower limb
arterial disease only ± and a further 188 (27%) also had
cardiac or cerebrovascular disease (Table 1). Of the 697
new referrals 163 patients (23%) were on a statin at
presentation but less than half (72; 44%) were being
treated adequately.
Of those patients with lower limb disease 70 (14%)
had a cholesterol 55 mmol/l and were not already on
a statin. Similarly, of patients with cardiac disease 31
(12%) had a cholesterol 55.0 mmol/l and were not on
a statin. Only 44 of 252 (17%) patients with PVD only
who should have been on a statin, were receiving lipid
lowering medication. For comparison, 107 of 223
(46%) of those with cardiac disease were receiving
lipid lowering medication.
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Table 1. Absolute numbers of the whole patient cohort with lower
limb arterial disease and numbers on a statin. The table has been
divided into those with a cholesterol less than and greater or equal
to 5 mmol/l.
Whole group Cholesterol
5 mmol/l
Cholesterol
5 mmol/l
Total On
statin
Total On
statin
Total On
statin
All patients 697 163 187 72 510 91
Patients with PVD 485 123 125 55 360 68
PVD alone 297 44 57 12 240 32
PVDCHD/stroke 188 79 68 43 120 36
Patients without PVD 212 40 62 17 150 23
CHD/stroke 66 28 18 12 48 16
PVDperipheral vascular disease, CHD coronary heart disease.
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Comment
Eighty-four per cent of new patients with intermittent
claudication have an indication for lipid lowering
according to current criteria. Of those on a statin,
many were inadequately treated, suggesting sub-
therapeutic dosing. The relatively low prescribing
rate of statins in our new referrals with claudication
reflects a general lack of awareness of this important
aspect of vascular management in the wider medical
community. The vascular outpatient clinic is an ideal
place for the identification of patients with hypercho-
lesterolaemia. Potentially, the vascular clinic is also
has an important contribution to make in monitoring
therapy and in the primary and secondary prevention
of coronary heart disease. A cardiovascular risk evalua-
tion and serum lipid measurement should be a com-
pulsory part of any outpatient vascular assessment.
The vast majority of patients with intermittent clau-
dication already have an indication for lipid lowering
therapy irrespective of any effect this may have spe-
cifically on their peripheral arterial disease. It is there-
fore unlikely that any placebo-controlled study trial
could ever take place to specifically assess the effects
of lipid lowering in peripheral vascular disease. The
answer to the question `` should all claudicants be on a
statin?'' is probably `` yes''. Rather than asking `` if''
claudicants require statin therapy we should be prob-
ably be concentrating on the issue of `` how low'' we
should get the cholesterol for maximum benefit.
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